John Martignetti, MD, PhD, Network Director of the Laboratory for Translational Research at the Western Connecticut Health Network (WCHN) Rudy L. Ruggles Biomedical Research Institute and colleagues at both WCHN and the Icahn School of Medicine at Mount Sinai, published a report that highlights the potential for an early ovarian cancer and endometrial cancer diagnostic tool. The report suggests that a novel liquid biopsy technique may be a powerful diagnostic tool where currently there is no early screening test for either ovarian or endometrial cancer.
- The early detection of endometrial and ovarian cancers has been a focus for several years, and the research underway is making great strides. Progress is documented in a number of publications, including most recently the Cold Spring Harbor Journal of Molecular Case Studies. The article is titled “Detection of endometrial pre-cancer by a targeted gynecological cancer liquid biopsy”.
- The report highlights the potential of this novel liquid biopsy technique as a powerful diagnostic tool where currently there is no screening test for either ovarian or endometrial cancer.
- This liquid biopsy has the potential for earlier detection of endometrial cancer through a more comfortable, convenient, and cost-effective screening.
- For more information on WCHN research visit www.wchn.org. For more information on ovarian cancer visit the National Cancer Institute.
Early detection can save lives from cancers typically known as silent killers because symptom onset is often too late for effective treatment.
John Martignetti, MD, PhD. is available for interviews regarding this research. Dr. Martignetti is Director of the Laboratory for Translational Research, at the Rudy L. Ruggles Biomedical Research Institute at WCHN (Danbury, CT) and the Icahn School of Medicine at Mount Sinai in New York City.
Beginning October 9, 2018 and going forward
To learn more and to speak with Dr. Martignetti, please contact: